As shown in Figure 6A and 6B, IL-17A significantly enhanced the cytotoxicity of B cells against ESCC tumor cells when the ratio of effect to target was at 10:1 (Figure 6A, P = 0.008 for EC109 cells; Figure 6B, P = 0.013 for KYSE 30 cells, respectively). This evidence concerns the gene IL17A and neoplasm.